iRadimed (NASDAQ:IRMD) Sets New 52-Week High – Here’s Why

Shares of iRadimed Corporation (NASDAQ:IRMD) reached a new 52-week high on Thursday . The stock traded as high as $88.72 and last traded at $87.4610, with a volume of 3558 shares. The stock had previously closed at $86.59.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Weiss Ratings reissued a “buy (b)” rating on shares of iRadimed in a research note on Friday, October 31st. Roth Capital set a $90.00 price objective on iRadimed in a research report on Friday, October 31st. Lake Street Capital reissued a “buy” rating and set a $100.00 target price on shares of iRadimed in a research note on Monday, November 3rd. Wall Street Zen lowered shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Finally, Zacks Research upgraded shares of iRadimed to a “hold” rating in a report on Tuesday, November 4th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $87.33.

iRadimed Stock Up 1.3%

The stock has a fifty day moving average of $76.56 and a 200-day moving average of $66.73. The firm has a market capitalization of $1.12 billion, a P/E ratio of 54.16 and a beta of 1.04.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.04. iRadimed had a return on equity of 23.30% and a net margin of 26.61%.The firm had revenue of $21.20 million during the quarter, compared to the consensus estimate of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS. FY 2025 guidance at 1.840-1.880 EPS. Sell-side analysts predict that iRadimed Corporation will post 1.66 EPS for the current fiscal year.

iRadimed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, November 25th. Shareholders of record on Friday, November 14th will be paid a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 0.8%. The ex-dividend date is Friday, November 14th. iRadimed’s payout ratio is presently 41.21%.

Insider Buying and Selling

In other news, CEO Roger E. Susi sold 5,000 shares of the stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $85.59, for a total transaction of $427,950.00. Following the completion of the transaction, the chief executive officer directly owned 2,312,500 shares in the company, valued at $197,926,875. This represents a 0.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last quarter, insiders have sold 45,000 shares of company stock worth $3,388,850. Insiders own 36.80% of the company’s stock.

Institutional Trading of iRadimed

Several institutional investors and hedge funds have recently bought and sold shares of the stock. CWM LLC grew its position in shares of iRadimed by 62.2% in the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 211 shares during the period. Quarry LP bought a new position in iRadimed during the third quarter worth about $40,000. Tower Research Capital LLC TRC increased its holdings in shares of iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares during the period. State of Alaska Department of Revenue acquired a new stake in shares of iRadimed in the third quarter valued at approximately $47,000. Finally, Spire Wealth Management bought a new stake in shares of iRadimed in the second quarter valued at approximately $60,000. Institutional investors own 92.34% of the company’s stock.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.